# ![@Biopharma_Watch Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1734221906151165952.png) @Biopharma_Watch BiopharmaWatch

BiopharmaWatch posts on X about $ocea, $ptpi, market, ticker the most. They currently have [-----] followers and [----] posts still getting attention that total [---] engagements in the last [--] hours.

### Engagements: [---] [#](/creator/twitter::1734221906151165952/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1734221906151165952/c:line/m:interactions.svg)

- [--] Week [------] +28%
- [--] Month [------] +71%
- [--] Months [-------] +49%
- [--] Year [-------] +127%

### Mentions: [--] [#](/creator/twitter::1734221906151165952/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1734221906151165952/c:line/m:posts_active.svg)

- [--] Month [---] -9%
- [--] Months [-----] +80%
- [--] Year [-----] +2,482%

### Followers: [-----] [#](/creator/twitter::1734221906151165952/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1734221906151165952/c:line/m:followers.svg)

- [--] Week [-----] +1.40%
- [--] Month [-----] +6%
- [--] Months [-----] +36%
- [--] Year [-----] +130%

### CreatorRank: [---------] [#](/creator/twitter::1734221906151165952/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1734221906151165952/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[stocks](/list/stocks)  [cryptocurrencies](/list/cryptocurrencies)  [finance](/list/finance)  [exchanges](/list/exchanges)  [currencies](/list/currencies)  [countries](/list/countries)  [technology brands](/list/technology-brands)  [financial services](/list/financial-services)  [travel destinations](/list/travel-destinations)  [automotive brands](/list/automotive-brands) 

**Social topic influence**
[$ocea](/topic/$ocea) #6, [$ptpi](/topic/$ptpi) #3, [market](/topic/market), [ticker](/topic/ticker) #270, [volume](/topic/volume) #495, [nasdaq](/topic/nasdaq), [$tnfa](/topic/$tnfa), [announces](/topic/announces), [$wint](/topic/$wint), [business](/topic/business)

**Top accounts mentioned or mentioned by**
[@monacobiotech](/creator/undefined) [@maximusholla](/creator/undefined) [@boudin420](/creator/undefined) [@randylus](/creator/undefined) [@olddogwthnwtrix](/creator/undefined) [@goderguy](/creator/undefined) [@aponiaanalytics](/creator/undefined) [@parasbiotech](/creator/undefined) [@solafsson](/creator/undefined) [@bkfviking123](/creator/undefined) [@jq1234t](/creator/undefined) [@martinshkreli](/creator/undefined) [@biostocks](/creator/undefined) [@yaireinhorn](/creator/undefined) [@amaymd](/creator/undefined) [@biotech2k1](/creator/undefined) [@biotechanalysst](/creator/undefined) [@home](/creator/undefined) [@pharmdabbler](/creator/undefined)

**Top assets mentioned**
[Taraxa (TARA)](/topic/$tara) [Regeneron Pharmaceuticals Inc (REGN)](/topic/$regn) [Magic Eden (ME)](/topic/$me) [Moderna Inc (MRNA)](/topic/$mrna) [Biomea Fusion, Inc. (BMEA)](/topic/$bmea) [Cytokinetics Inc. (CYTK)](/topic/$cytk) [Halozyme Therapeutics, Inc. (HALO)](/topic/$halo) [Gain Therapeutics, Inc. (GANX)](/topic/$ganx) [Iovance Biotherapeutics, Inc. Common Stock (IOVA)](/topic/$iova) [Bristol-Myers Squibb Co (BMY)](/topic/$bmy) [Merck & Co., Inc. (MRK)](/topic/$mrk) [Ocular Therapeutix, Inc. (OCUL)](/topic/$ocul) [Mist (MIST)](/topic/$mist) [Travere Therapeutics, Inc. Common Stock (TVTX)](/topic/$tvtx) [IN8bio, Inc. (INAB)](/topic/$inab) [Pfizer, Inc. (PFE)](/topic/$pfe) [Sagimet Biosciences Inc. (SGMT)](/topic/$sgmt) [Rhythm Pharmaceuticals, Inc. Common Stock (RYTM)](/topic/$rytm) [Cogent Biosciences, Inc. Common Stock (COGT)](/topic/$cogt) [Geron Corp (GERN)](/topic/$gern) [CRISPR Therapeutics AG (CRSP)](/topic/$crsp) [BridgeBio Pharma, Inc. Common Stock (BBIO)](/topic/$bbio) [ALX Oncology Holdings Inc (ALXO)](/topic/$alxo) [Pharming Group N.V. (PHAR)](/topic/$phar) [IO Biotech, Inc. (IOBT)](/topic/$iobt) [Acumen Pharmaceuticals, Inc. (ABOS)](/topic/$abos) [Olema Pharmaceuticals, Inc. (OLMA)](/topic/$olma) [Pasithea Therapeutics Corp. (KTTA)](/topic/$ktta) [Mirum Pharmaceuticals, Inc. Common Stock (MIRM)](/topic/$mirm) [Alnylam Pharmaceuticals, Inc. (ALNY)](/topic/$alny) [4D Molecular Therapeutics Inc. (FDMT)](/topic/$fdmt) [TG Therapeutics, Inc. (TGTX)](/topic/$tgtx) [AstraZeneca PLC (AZN)](/topic/$azn) [Annovis Bio Inc. (ANVS)](/topic/$anvs) [bioAffinity Technologies, Inc. (BIAF)](/topic/$biaf) [Connect Biopharma Holdings Limited (CNTB)](/topic/$cntb) [HCW Biologics Inc. (HCWB)](/topic/$hcwb)
### Top Social Posts
Top posts by engagements in the last [--] hours

"Gilead Sciences $GILD experienced its largest decline in stock value in the past ten years"  
[X Link](https://x.com/anyuser/status/1749717471085371647)  2024-01-23T08:55Z [----] followers, [---] engagements


"Which were expected today from this $NEXI $PEPG $GRI $SANM $ATPC $ZYSA $CRBP $VIVOS $IXHL $LMDX $SXTP $NYXH $REVB $PALI $CNSP $IMPL $LGVN $MOTS https://www.biopharmawatch.com/volatile-Data https://www.biopharmawatch.com/volatile-Data"  
[X Link](https://x.com/Biopharma_Watch/status/1752415847090462994)  2024-01-30T19:37Z [---] followers, [----] engagements


"2024 Will Be a Buyers Market in Biopharma. It Already Is: Catalent to Novo JnJ to acquire Ambrx for $2 B Gileads $4.3 B acquisition of CymaBay BMS $4 billion acquisition of Rayzebio and Pfizers $43 B acquisition of Seagen. PWC says this could reach $250 billion Double"  
[X Link](https://x.com/anyuser/status/1761364010136387713)  2024-02-24T12:14Z [----] followers, [---] engagements


"Today's Most Volatile: Gainers: $AKLI: +121.12% $OCEA: +57.96% $KRYS: +37.84% $MIST: +32.94% $BFLY: +32.35% $NEPT: +32.31% $ZVSA: +29.03% Losers: $LMDX: -53.49% $MDVL: -40.59% $NSTG: -37.43% $NVIV: -34.28% $IMPL: -27.27% $VERO: -24.62% $RNAC: -24.44%"  
[X Link](https://x.com/anyuser/status/1762219270526607683)  2024-02-26T20:53Z [----] followers, [----] engagements


"Upcoming Biotech and Pharma FDA/Catalyst Calendar for March 2024: $IRWD $EYEN $EYPT $VNDA $BCDA $BMEA $MIRM $MDGL $GERN $BMY $OPTN $ORTX $VRTX $MRK $AKBA $CRSP $TVTX $RNA Check out more catalysts: https://www.biopharmawatch.com/fda-calendar https://www.biopharmawatch.com/fda-calendar"  
[X Link](https://x.com/anyuser/status/1762243018713661762)  2024-02-26T22:27Z [----] followers, [----] engagements


"@monaco_biotech Also many insiders got into that wave.right before the DEERFIELD"  
[X Link](https://x.com/anyuser/status/1762244479723896974)  2024-02-26T22:33Z [----] followers, [--] engagements


"Upcoming FDA/PDUFA catalysts calendar (*Updated) for mainly the first two weeks of March 2024: $SLS $EYEN $VNDA $BCDA $RNA $WVE $VNDA $BMEA $EWTX $VYNE $MNMD $MLTX $MIRM $MDGL $GERN $BMY $OPTN $ORTX $VRTX $MRK $AKBA $CRSP $TVTX https://www.biopharmawatch.com/ https://www.biopharmawatch.com/"  
[X Link](https://x.com/anyuser/status/1764342073145061636)  2024-03-03T17:28Z [----] followers, [----] engagements


"Top [--] Potential Biotech buyout in 2024: 1) Argenx $ARGX: A Belgian biotech company developing antibody-based therapies. It is a potential target for its robust clinical pipeline particularly its efgartigimod product for generalized myasthenia gravis"  
[X Link](https://x.com/anyuser/status/1764730092595347858)  2024-03-04T19:10Z [----] followers, [---] engagements


"2) Arrowhead Pharmaceuticals $ARWR: An American biopharmaceutical company developing RNA interference (RNAi) therapeutics for various diseases including liver and metabolic disorders. Its innovative RNAi technology and promising pipeline make it attractive for acquisition"  
[X Link](https://x.com/anyuser/status/1764730094453416223)  2024-03-04T19:10Z [----] followers, [---] engagements


"5) BioMarin Pharmaceutical Inc. $BMRN: An American biotechnology company developing and commercializing gene therapies for rare diseases. Its established gene therapy platform and successful products like Vimizim for Morquio A syndrome could spark acquisition interest"  
[X Link](https://x.com/Biopharma_Watch/status/1764730100073820528)  2024-03-04T19:10Z [---] followers, [---] engagements


"7) hVIVO plc $HVO: A CRO specializing in conducting early-phase clinical trials for pharmaceutical and biotechnology companies. Its expertise in conducting human challenge studies could attract acquisition interest from larger companies seeking to accelerate drug development"  
[X Link](https://x.com/Biopharma_Watch/status/1764730103542554643)  2024-03-04T19:10Z [---] followers, [---] engagements


"8) Intra-Cellular Therapies Inc. $ITCI: An American biopharma developing drugs for central nervous system (CNS) disorders and other indications. Its diverse pipeline including products for Parkinson's disease and schizophrenia could be attractive for acquisition"  
[X Link](https://x.com/Biopharma_Watch/status/1764730105350287514)  2024-03-04T19:10Z [---] followers, [---] engagements


"What do you think about this analysis and feel free to add more that you think can be on this list"  
[X Link](https://x.com/Biopharma_Watch/status/1764730111113183364)  2024-03-04T19:10Z [---] followers, [---] engagements


"Upcoming FDA/PDUFA catalysts calendar (*Updated) for mid-March 2024: $MIRM $MDGL $GERN $BMY $LEGN $TSTV $OPTN $ORTX $VRTX $MRK $AKBA $CRSP $TVTX Full Calendar: https://www.biopharmawatch.com/ https://www.biopharmawatch.com/"  
[X Link](https://x.com/anyuser/status/1767167607914815554)  2024-03-11T12:36Z [----] followers, [----] engagements


"Biotech and Pharma Stock FDA/PDUFA Catalyst Calendar for end-March/April [----] (Thread)"  
[X Link](https://x.com/Biopharma_Watch/status/1771229993063870657)  2024-03-22T17:38Z [---] followers, [---] engagements


"$MRK: Awaiting PDUFA date on 2024-03-26 for Sotatercept a Pulmonary Arterial Hypertension (PAH) treatment. $AKBA: Vadadustat targeting Anemia due to chronic kidney disease has a PDUFA date set for 2024-03-27"  
[X Link](https://x.com/Biopharma_Watch/status/1771229994821234967)  2024-03-22T17:38Z [---] followers, [---] engagements


"$OCUL: PAXTRAVA (OTX-TIC) Phase [--] data readout for Ocular hypertension Primary open-angle glaucoma expected on April [--]. $IMGN: ELAHERE (Mirvetuximab Soravtansine) has a PDUFA date of 2024-04-05 for Cancer specifically Ovarian cancer"  
[X Link](https://x.com/Biopharma_Watch/status/1771230001964159415)  2024-03-22T17:38Z [---] followers, [---] engagements


"Upcoming FDA/PDUFA catalysts calendar (*Updated) for mainly the end of March/April 2024: $MRK $AKBA $CRSP $ALRN $BIOC $NVCR $SUPN $LEGN $OCUL $IMGN $ALNY $KZIA $CRDF $ELIO $NGM $MRNA $KRON $ATOS $RAPT $XBI $IBB https://www.biopharmawatch.com/ https://www.biopharmawatch.com/"  
[X Link](https://x.com/anyuser/status/1772223375768760752)  2024-03-25T11:25Z [----] followers, [----] engagements


"@Maximus_Holla Yes you need to register alternatively you can also use Google sign-in. Thank you"  
[X Link](https://x.com/anyuser/status/1772259384812253388)  2024-03-25T13:48Z [----] followers, [--] engagements


"Upcoming FDA/PDUFA catalysts calendar (*Updated) for the end of April and May [----] Full Free Access here: $AQST $KALV $XFOR $CATX $XOMA $DAWN $CRVS $NBIX $LCTX $PHIO $NGNE $FATE $AZTR $RNAC $DVAX $CYTK $ASND $ADXN https://biopharmawatch.com/fda-calendar https://biopharmawatch.com/fda-calendar"  
[X Link](https://x.com/anyuser/status/1783122208044249589)  2024-04-24T13:13Z [----] followers, [----] engagements


"Upcoming FDA/PDUFA Catalysts Calendar for the end of May and June [----] Full Free Access here: $AVTE $IRWD $PLRX $INSM $BMY $ABEO $BHVN $MGNX $SWTX $IOVA $MOR $NXTC $CYCC $MURA $RCUS $BGNE $KRON $ERAS $SNSE $CRBP $ME $JAZZ $BDTX https://biopharmawatch.com https://biopharmawatch.com"  
[X Link](https://x.com/anyuser/status/1792975833654546900)  2024-05-21T17:48Z [----] followers, [----] engagements


"$IOBT $BCAB $CARM $PPBT $MNOV $EVGN $SWTX $BGNE $CPRX $PLRX Full Free Access here: More Catalysts in June: $FDMT $ABUS $SRZN $SGMT $GSK $DRRX $LPCN $GNFT $REGN $AMGN $MBRX $KYMR $AUTL $EDIT $INAB https://biopharmawatch.com https://biopharmawatch.com"  
[X Link](https://x.com/Biopharma_Watch/status/1792975837903380510)  2024-05-21T17:48Z [---] followers, [----] engagements


"Upcoming catalyst for this week: $RNA $NVS $KYMR $MBRX $URGN $INAB $EDIT $AUTL $PTGX $IRON $KROS $EPIX $GMAB Look for more on the: https://www.biopharmawatch.com/fda-calendar https://www.biopharmawatch.com/fda-calendar"  
[X Link](https://x.com/Biopharma_Watch/status/1801196461251785074)  2024-06-13T10:14Z [---] followers, [----] engagements


"PDUFAs for June and July: $GSK $GNFT $REGN $AMGN $ZLAB $GHRS $GERN $LGND $MRK $ARGX $XOMA $ZLAB $RCKT $ARQT The full free version of Caledar is here: https://www.biopharmawatch.com/PDUFA-calendar https://www.biopharmawatch.com/PDUFA-calendar"  
[X Link](https://x.com/Biopharma_Watch/status/1801196466024710419)  2024-06-13T10:14Z [---] followers, [---] engagements


"A sneak pick of the Small-Mid Caps Heatmap interactive version is here: $IBRX $DYN $VCEL $RXRX $BPMC $ADMA $BBIO $HALO $TGTX $NUVL $CERE $ROIV $PTCT $RYTM $PCVX $CGON $SMMT $APGE $ARWR $RARE $GERN $RNA $MRUS $FOLD $LEGN https://biopharmawatch.com/heatmap https://biopharmawatch.com/heatmap"  
[X Link](https://x.com/Biopharma_Watch/status/1803379588480815451)  2024-06-19T10:49Z [---] followers, [----] engagements


"Intellia Therapeutics $NTLA Drug: NTLA-2001Stage: Phase [--] Treatment: Transthyretin (ATTR) amyloidosis Catalyst Date: 2024-06-25 Probability of Approval: Approximately 14% for Phase [--] rare disease drugs https://biopharmawatch.com/company/NTLA https://biopharmawatch.com/company/NTLA"  
[X Link](https://x.com/Biopharma_Watch/status/1804298607450796377)  2024-06-21T23:41Z [---] followers, [---] engagements


"Verona Pharma plc $VRNA Drug: EnsifentrineStage: NDA Treatment: COPD Catalyst Date: 2024-06-26 Probability of Approval: Over 85% typical for NDA submissions in respiratory diseases. Hedge fund Holding: 1/34 https://biopharmawatch.com/company/VRNA https://biopharmawatch.com/company/VRNA"  
[X Link](https://x.com/Biopharma_Watch/status/1804298610000920853)  2024-06-21T23:41Z [---] followers, [---] engagements


"Biophytis SA $BPTS Drug: SarconeosStage: NDA Treatment: COVID-19 Catalyst Date: 2024-06-30 Probability of Approval: Over 85% typical for NDA submissions in infectious diseases. https://biopharmawatch.com/company/BPTS https://biopharmawatch.com/company/BPTS"  
[X Link](https://x.com/Biopharma_Watch/status/1804298619501113448)  2024-06-21T23:41Z [---] followers, [---] engagements


"Aldeyra Therapeutics Inc $ALDX Drug: Reproxalap (ADX-102)Stage: NDA Treatment: Dry Eye Disease Catalyst Date: 2024-06-30 Probability of Approval: Over 85% typical for NDA submissions in ophthalmology. Hedge fund Holding: 3/34 https://biopharmawatch.com/company/ALDX https://biopharmawatch.com/company/ALDX"  
[X Link](https://x.com/Biopharma_Watch/status/1804298623003357209)  2024-06-21T23:41Z [---] followers, [---] engagements


"Top High-Growth Oncology Drug Targets in 2024-2028 $XBI"  
[X Link](https://x.com/Biopharma_Watch/status/1809166946669039775)  2024-07-05T10:06Z [---] followers, [---] engagements


"PD-1/PD-L1 Inhibitors $MRK with Keytruda (pembrolizumab) leads in NSCLC and other cancers. $BMY with Opdivo (nivolumab) has numerous trials in melanoma and renal cell carcinoma. CTLA-4 Inhibitors $BMY with Yervoy (ipilimumab) in combo therapies with PD-1 inhibitors"  
[X Link](https://x.com/Biopharma_Watch/status/1809167878303703283)  2024-07-05T10:10Z [---] followers, [---] engagements


"HER2 Inhibitors Genentech (Roche $RHHBY) with Herceptin (trastuzumab) for HER2-positive breast cancer KRAS Inhibitors $AMGN with Lumakras (sotorasib) targeting KRAS G12C in NSCLC BRAF Inhibitors $NVS with Tafinlar (dabrafenib) and Mekinist (trametinib) for melanoma"  
[X Link](https://x.com/Biopharma_Watch/status/1809167880296030353)  2024-07-05T10:10Z [---] followers, [---] engagements


"TIGIT Inhibitors $GILD advancing TIGIT inhibitors LAG-3 Inhibitors $BMY with relatlimab leading in LAG-3 inhibitors CDK4/6 Inhibitors $PFE with Ibrance (palbociclib) for hormone receptor-positive breast cancer EGFR Inhibitors $AZN with Tagrisso for EGFR-mutated NSCLC"  
[X Link](https://x.com/Biopharma_Watch/status/1809167882057589164)  2024-07-05T10:10Z [---] followers, [---] engagements


"VEGFR Inhibitors $LLY with ramucirumab targeting various cancers IDH1/2 Inhibitors $AGIO with ivosidenib for IDH1 mutations in leukemia PARP Inhibitors $AZN with olaparib in ovarian and breast cancers"  
[X Link](https://x.com/Biopharma_Watch/status/1809167884117008443)  2024-07-05T10:10Z [---] followers, [---] engagements


"PSMA Inhibitors $NVS with radioligand therapies for prostate cancer. BCMA Inhibitors $BMY with Abecma (idecabtagene vicleucel) for multiple myeloma. CD19 Inhibitors $GILD with Yescarta (axicabtagene ciloleucel) a CAR-T therapy for B-cell lymphomas"  
[X Link](https://x.com/Biopharma_Watch/status/1809167885945778580)  2024-07-05T10:10Z [---] followers, [---] engagements


"Upcoming FDA/PDUFA Catalysts Calendar for the end of July Full Free Access here: $ARGX $ADVM $FDMT $BIVI $ALGS $OCUL $ANNX $PHAT $IONS $JAGX $CLRB $CLSD $CGTX $LGMN $ABOS https://biopharmawatch.com https://biopharmawatch.com"  
[X Link](https://x.com/anyuser/status/1813332207479734649)  2024-07-16T21:57Z [----] followers, [----] engagements


"A sneak pick of the Small-Mid Caps Heatmap interactive version is here: $SMMT $RXRX $JANX $IONS $APGE $DNLI $RARE $BEAM $DYN $RVMD $CRSP $RCKT $PCVX $AXSM $KRYS $BHVN $CERE $VKTX $IDYA $ADMA $CYTK $PTCT $ROIV $XENE $SAVA $HUMA https://biopharmawatch.com/heatmap https://biopharmawatch.com/heatmap"  
[X Link](https://x.com/Biopharma_Watch/status/1815797321222774954)  2024-07-23T17:13Z [---] followers, [----] engagements


"Upcoming PDUFA Catalysts Calendar for August [----] Full Free Access here: $ADAP $HUMA $CTXR $ASND $GILD $ICPT $AGIO $RPRX $REGN $INCY $SNDX https://biopharmawatch.com https://biopharmawatch.com"  
[X Link](https://x.com/Biopharma_Watch/status/1818769924812357970)  2024-07-31T22:05Z [---] followers, [----] engagements


"Upcoming Catalysts Calendar for the full version check out: $INCY $SNDX $AGEN $CYTK $TVTX $LGND $AVDL $NVCR $AVBP $IFRX $NUVB $ADAG. https://www.biopharmawatch.com/fda-calendar https://www.biopharmawatch.com/fda-calendar"  
[X Link](https://x.com/anyuser/status/1824205895493984467)  2024-08-15T22:05Z [----] followers, [----] engagements


"Upcoming Catalysts Calendar: Sep [----] for the full version check out: $AGEN $GANX $CYTK $ARWR $TVTX $TVTX $LGND $AVDL $REGN $PLRX $NVCR $SMMT $GOSS $LBRP $AVBP https://biopharmawatch.com/fda-calendar https://biopharmawatch.com/fda-calendar"  
[X Link](https://x.com/anyuser/status/1830722870097465769)  2024-09-02T21:42Z [----] followers, [----] engagements


"Upcoming Catalysts Calendar: Sep [----] for the full version check out: $CAPR $VNDA $FOMT $IMNN $ANNX $ZVRA $KRON $HRTX $CLDX $PSTX $MRK $ORKA $CNTA $ZLAB $KRTX $SGMT $ENTX $PSTV $BBIO $CMND $EXEL $AADI https://www.biopharmawatch.com/fda-calendar https://www.biopharmawatch.com/fda-calendar"  
[X Link](https://x.com/anyuser/status/1836112821026705835)  2024-09-17T18:39Z [----] followers, [----] engagements


"Approval Odds for $CLDX $PSTX $ANIX $SGMT $ENTX $PSTV & $BBIO (Thread) $CLDX Barzolvolimab (CSU Phase 2) Probability of approval: 70-75% Strong symptom relief (51%) in resistant CSU patients. Favorable safety profile with high unmet needs. Likely Phase [--] move"  
[X Link](https://x.com/anyuser/status/1836534286645674200)  2024-09-18T22:34Z [----] followers, [----] engagements


"Upcoming Catalysts Calendar for October [----] for the full version check out: $WINT $PDSB $ELTX $CDTX $OCUL $ABOS $SPRY $VERA $LUMO $BFI $KALV $ENSC $GANX $CLSD $TBRD $MIST $PHIO $STRO https://biopharmawatch.com/fda-calendar https://biopharmawatch.com/fda-calendar"  
[X Link](https://x.com/anyuser/status/1840784772521418909)  2024-09-30T16:04Z [----] followers, [----] engagements


"Our Top [--] BioPharma Picks from Q2 Bio Hedge Funds Data 👇 $INSM $MRUS $PCVX $EWTX $DYN $GPCR $IMVT $VRDN $XENE $CYTK Return from August [--] 2024: +11.41% Last [--] Month: +12.63% Last [--] Year: +111.97% 🚀 You can follow them at: https://biopharmawatch.com/allstockshold https://biopharmawatch.com/allstockshold"  
[X Link](https://x.com/anyuser/status/1843755032761831548)  2024-10-08T20:47Z [----] followers, [----] engagements


"Upcoming Catalysts Calendar: November [----] heres the full version: $LPCN $ANIX $LENZ $LYEL $ATXS $UXBX $LXRX $MIRM $REPL $ICCM $MNK $CADL $MIURA $CNTX $XLO $RCUS $ADAG $IOVA $SIBK $HOOK $NAVA $NGNE $LRMR https://biopharmawatch.com/fda-calendar https://biopharmawatch.com/fda-calendar"  
[X Link](https://x.com/anyuser/status/1853845939326431693)  2024-11-05T17:04Z [----] followers, [----] engagements


"Upcoming PDUFAs to watch in [----]. The full version available here: $AUTL $APLT $BBIO $JAZZ $ZYME $IONS $LXRX $SNDX $RYTM $SLNO $CKPT $NBIX https://biopharmawatch.com/fda-calendar https://biopharmawatch.com/fda-calendar"  
[X Link](https://x.com/anyuser/status/1856291572419330110)  2024-11-12T11:02Z [----] followers, [----] engagements


"Our latest release from the Oncology [--] portfolio has delivered impressive results achieving a 4.78% last month and a remarkable annual return of 98.46% 🚀 Open to feedback ✌ $NRIX $CNTA $SNDX $GLPG $IMCR $BCYC $XNCR $KURA $AVBP $CSTL"  
[X Link](https://x.com/anyuser/status/1856385034590269451)  2024-11-12T17:14Z [----] followers, [----] engagements


"Upcoming Catalysts to Watch in the Next Few Weeks: $APLT $BRIO $JAZZ $ZYME $TLSA $IKT $AVIR $INAB $AZN $CCXI $MRUS $MNOV $SNDX $JNJ $BGNE $GERN $FATE $ADCT For detailed insights and full coverage visit http://BiopharmaWatch.com http://BiopharmaWatch.com"  
[X Link](https://x.com/anyuser/status/1860661612689989853)  2024-11-24T12:27Z [----] followers, [----] engagements


"Upcoming Catalysts to Watch in the Next Weeks: $JAGX $OCGN $URGN $MNOV $FATE $GERN $KURA $SNDX $BGNE $ADCT $DRUG $REGN $MRUS $SLS $JNJ $CCCC $IRON $STOK $COGT $BLUE $AGIO $AKRO $RHAC $KRON $CRSP $NVO For detailed insights: http://BiopharmaWatch.com http://BiopharmaWatch.com"  
[X Link](https://x.com/anyuser/status/1864358541210902987)  2024-12-04T17:18Z [----] followers, [----] engagements


"Upcoming Catalysts to Watch in the Next Weeks: $JAGX $BCTX $CYBN $EPIX $EVOX $ALXO $ITOS $TGTX $IMMP $AMLX $GUTS $OKUR $PSTV $BCAB $TNXP $AFMD $IONS $THTX $LXRX $SNDX For detailed insights: http://BiopharmaWatch.com http://BiopharmaWatch.com"  
[X Link](https://x.com/anyuser/status/1866901366108504154)  2024-12-11T17:42Z [----] followers, [----] engagements


"Upcoming Catalysts to Watch in the year-end: $EVTX $IONS $LXRX $RYTM $SNDX $MIRM $FBIO $CKPT $NBIX $BMY $PSTX $IPSC $PRTC For detailed insights: https://biopharmawatch.com/fda-calendar https://biopharmawatch.com/fda-calendar"  
[X Link](https://x.com/anyuser/status/1869279798507487378)  2024-12-18T07:13Z [----] followers, [----] engagements


"Full View of Market Movers: $TRDA $BTTX $CERS $CEI $ACHV $ATHX $PFE $PTPI $GRTS $VKTX $HBI $IPSC $GEVO $PLXP $ZYNX $SRRK $TEVA $MRNA $WBA $NVO $JNJ $AMGN $PLSE $ADCT $PHAT $ANVS $NYCT $AVDL $PAG $CTSO $RZLT $CERO $OMIC https://biopharmawatch.com/market-movers https://biopharmawatch.com/market-movers"  
[X Link](https://x.com/Biopharma_Watch/status/1869279803540709509)  2024-12-18T07:13Z [----] followers, [----] engagements


"Happy New Year Here are some new catalysts to kick things off: $VIR $EDSA $CKVD $AVXL $OLMA $NMRA $ATRA $MCRB $INKT $ALXO $XLO $CHRS $DRTS $APLT $ONCY $AGEN $BIII. Attention: Weve launched a new feature called PoA. Find out more here: https://biopharmawatch.com/fda-calendar https://biopharmawatch.com/fda-calendar"  
[X Link](https://x.com/Biopharma_Watch/status/1874926134003191899)  2025-01-02T21:09Z [---] followers, [----] engagements


"Upcoming catalysts to watch in mid-January 2025: $SHPH $AVXL $CVKD $EDSA $OLMA $NMRA $ATRA $MCRB $INKT $XLO $ALXO $ONCY $DTIL $CHRS $BIIB $AGEN For detailed insights: https://biopharmawatch.com/fda-calendar https://biopharmawatch.com/fda-calendar"  
[X Link](https://x.com/Biopharma_Watch/status/1878717195905372481)  2025-01-13T08:14Z [---] followers, [----] engagements


"Full View of Market Movers: $CNTA $BTTX $EPIX $CRBP $GBTG $MSTX $PRAX $TNON $VCNX $HROW $CBIO $FRTX $AVTX $GOSS $PMCB $WBA $MRNA $JNJ $AZN $PFE $NKTR $ARGX $TSLA $PASG $PRQR $RXDX $PLM $APTO $MURA $IKNG $CRBP $ONMU $ARQT https://biopharmawatch.com/market-movers https://biopharmawatch.com/market-movers"  
[X Link](https://x.com/Biopharma_Watch/status/1878717201307603241)  2025-01-13T08:14Z [----] followers, [----] engagements


"Upcoming biotech and pharma FDA/PDUFA Catalysts Calendar"  
[X Link](https://x.com/Biopharma_Watch/status/1880173374355239305)  2025-01-17T08:40Z [---] followers, 18.3K engagements


"Upcoming Catalysts for next week in Biotech and Pharma"  
[X Link](https://x.com/Biopharma_Watch/status/1880175477090078920)  2025-01-17T08:49Z [---] followers, 16.9K engagements


"Upcoming Catalyst Calendar for Biotech and Pharma (FDA/PDUFA): $INKT $XLO $NTRA $ALXO $ONCY $CHRS $DRTS $AGEN $BIIB $ZNTL here is a full view: https://biopharmawatch.com/fda-calendar https://biopharmawatch.com/fda-calendar"  
[X Link](https://x.com/anyuser/status/1881477268574478431)  2025-01-20T23:01Z [----] followers, [----] engagements


"Upcoming PDUFA Dates You Should Know 🚨 Biotech catalysts with major FDA decisions are on the horizon for early [----]. Heres what you need to know (Thread): 1/ Vertex Pharmaceuticals $VRTX 💊 Drug: Suzetrigine 📅 PDUFA Date: Jan [--] [----] 🩹 Indication: Moderate-to-Severe Acute Pain 🔍 Insight: Suzetrigine is a non-opioid pain medication aiming to address unmet needs in acute pain management. Priority review highlights its potential to minimize opioid-related risks. 💡 Why It Matters: Approval could position Vertex as a leader in non-opioid therapies. 📈 PoA: 80% 📖 Track it here:"  
[X Link](https://x.com/Biopharma_Watch/status/1881674354238292004)  2025-01-21T12:05Z [---] followers, [---] engagements


"4/ AstraZeneca $AZN 💊 Drug: ENHERTU 📅 PDUFA Date: Feb [--] [----] 💞 Indication: HER2-low Breast Cancer 🔍 Insight: ENHERTU is a targeted antibody-drug conjugate for HER2-low and ultra-low breast cancer. Promising data highlights its potential in addressing significant unmet needs. 💡 Why It Matters: Approval would expand HER2-targeted therapies to a broader population. 📈 PoA: 85% 📖 Track it here: https://biopharmawatch.com/fda-calendar https://biopharmawatch.com/fda-calendar"  
[X Link](https://x.com/Biopharma_Watch/status/1881674360924062134)  2025-01-21T12:05Z [---] followers, [---] engagements


"7/ SpringWorks Therapeutics $SWTX 💊 Drug: Mirdametinib 📅 PDUFA Date: Feb [--] [----] 🧬 Indication: NF1-PN (Neurofibromatosis Type 1-Associated Plexiform Neurofibromas) 🔍 Insight: Mirdametinib is an oral MEK inhibitor showing efficacy in reducing tumor size and improving symptoms in NF1-PN patients. 💡 Why It Matters: Represents a significant step forward in addressing a rare and underserved condition. 📈 PoA: 70% 📖 Track it here: https://biopharmawatch.com/fda-calendar https://biopharmawatch.com/fda-calendar"  
[X Link](https://x.com/Biopharma_Watch/status/1881674367098126360)  2025-01-21T12:05Z [---] followers, [---] engagements


"Upcoming Catalysts to Watch in the Next Weeks: $AZN $SUPN $MRUS $CYTH $ZVRA $FDMT $PFE $CRBP $STTK $ALMS $ETON $SWTX $HALO $ATHE $ANAB $SPRY $SCPH $OGN $ALNY $THTX $GSK $MIST $SLNO $SNY $DNLI $IRON $IPSC $INVA $PRAX $CRNX $IMMP $PBLA $RCKT $IOVA For detailed insights: https://biopharmawatch.com/fda-calendar https://biopharmawatch.com/fda-calendar"  
[X Link](https://x.com/anyuser/status/1885489009150812492)  2025-02-01T00:43Z [----] followers, [----] engagements


"Upcoming Catalysts to Watch at the End of March 2025: $CGON $NRXS $IMMP $GSK $SLNO $BCAB $MIST $NBTX $KTTA $SYN $SNY $BNTX $MYLS $CYTK $AMRN $BBIO $BCDA $CRNX For detailed insights: https://biopharmawatch.com/fda-calendar https://biopharmawatch.com/fda-calendar"  
[X Link](https://x.com/Biopharma_Watch/status/1904477781716603265)  2025-03-25T10:17Z [----] followers, [----] engagements


"$BNTX Catalyst Date - 2025-03-28 Drug - BNT327 (anti-PD-L1/VEGF-A bispecific antibody) Treatment - ES-SCLC https://www.biopharmawatch.com/company/BNTX https://www.biopharmawatch.com/company/BNTX"  
[X Link](https://x.com/Biopharma_Watch/status/1905232032306962442)  2025-03-27T12:14Z [---] followers, [--] engagements


"Highest Volume Ticker - Price - Volume $LXRX - 0.62$ - 248.2M $SNSE - 0.56$ - 129.1M $STSS - 0.04$ - 106.1M $CUTR - 0.10$ - 29.5M $WBA - 18.72$ - 28.8M https://biopharmawatch.com/market-movers https://biopharmawatch.com/market-movers"  
[X Link](https://x.com/Biopharma_Watch/status/1905651122871943539)  2025-03-28T16:00Z [---] followers, [---] engagements


"Highest Volume Ticker - Price - Volume $CTOR - 1.00$ - 58.2M $LXRX - 0.59$ - 49.2M $STSS - 0.03$ - 45.4M $ME - 0.61$ - 29.7M $CUTR - 0.10$ - 29.5M https://biopharmawatch.com/market-movers https://biopharmawatch.com/market-movers"  
[X Link](https://x.com/Biopharma_Watch/status/1906738284895846424)  2025-03-31T16:00Z [---] followers, [---] engagements


"Unusual Volume Ticker - Avg Vol - Cur Vol - Unusual Ratio $ECOR - 92.7K - 239.6K - [----] $STAA - 1.2M - 2.3M - [----] $TARA - 264.7K - 411.2K - [----] https://biopharmawatch.com/market-movers https://biopharmawatch.com/market-movers"  
[X Link](https://x.com/Biopharma_Watch/status/1906738285164269912)  2025-03-31T16:00Z [---] followers, [---] engagements


"Highest Volume Ticker - Price - Volume $BIAF - 0.77$ - 322.8M $STSS - 0.03$ - 297.4M $RSLS - 1.15$ - 152.6M $ME - 0.61$ - 29.7M $CUTR - 0.10$ - 29.5M https://biopharmawatch.com/market-movers https://biopharmawatch.com/market-movers"  
[X Link](https://x.com/Biopharma_Watch/status/1907100673163792883)  2025-04-01T16:00Z [---] followers, [---] engagements


"Latest catalysts: $CING Catalyst Date - 2025-04-02 Drug - CTx-1301 (dexmethylphenidate) Treatment - Attention Deficit Hyperactivity Disorder (ADHD) https://biopharmawatch.com/fda-calendar https://biopharmawatch.com/fda-calendar"  
[X Link](https://x.com/Biopharma_Watch/status/1907463061964771577)  2025-04-02T16:00Z [---] followers, [---] engagements


"Unusual Volume Ticker - Avg Vol - Cur Vol - Unusual Ratio $ECOR - 92.7K - 239.6K - [----] $HALO - 1.0M - 1.5M - [----] $MRNA - 13.6M - 18.9M - [----] https://biopharmawatch.com/market-movers https://biopharmawatch.com/market-movers"  
[X Link](https://x.com/Biopharma_Watch/status/1907463062853960168)  2025-04-02T16:00Z [---] followers, [---] engagements


"$ARGX Catalyst Date - 2025-04-05 Drug - VYVGART (efgartigimod alfa-fcab) Treatment - generalized myasthenia gravis (gMG) chronic inflammatory demyelinating polyneuropathy (CIDP) https://www.biopharmawatch.com/company/ARGX https://www.biopharmawatch.com/company/ARGX"  
[X Link](https://x.com/Biopharma_Watch/status/1907463110027252128)  2025-04-02T16:00Z [---] followers, [---] engagements


"Upcoming catalysts to watch in April [----] 📅: $CING $ALDX $RPRX $EXEL $ARGX $TGTX $PRAX $CNTA $GANX $RAPP $PMN $THTX $REGN $BMY $NBTX $ITOS $AAPG $BCAX $TLX $CGON $OLMA $KURA $COGT $FHTX $IOBT $NVCT For detailed insights 📷 https://biopharmawatch.com/fda-calendar https://biopharmawatch.com/fda-calendar"  
[X Link](https://x.com/anyuser/status/1907559047554801844)  2025-04-02T22:21Z [----] followers, [----] engagements


"Top Market Movers: Positive News Full Access: $OSRH 2.67$ 81.63% April [--] [----] OSR Holdings Inc. (NASDAQ: OSRH) Enters Into $80 Million Common Stock Purchase Agreement With White Lion GBM Innovation Fund With An Eye Towar https://biopharmawatch.com/market-movers https://biopharmawatch.com/market-movers"  
[X Link](https://x.com/Biopharma_Watch/status/1907825441349738739)  2025-04-03T16:00Z [----] followers, [---] engagements


"$IPHA 1.95$ 8.94% April [--] [----] Innate Pharma to Participate in the [----] Stifel Virtual Targeted Oncology Forum"  
[X Link](https://x.com/Biopharma_Watch/status/1907825443119706276)  2025-04-03T16:00Z [----] followers, [---] engagements


"Latest catalysts: $TGTX Catalyst Date - 2025-04-05 Drug - BRIUMVI (ublituximab-xiiy) Treatment - relapsing forms of multiple sclerosis (RMS) https://biopharmawatch.com/fda-calendar https://biopharmawatch.com/fda-calendar"  
[X Link](https://x.com/Biopharma_Watch/status/1907825445753790930)  2025-04-03T16:00Z [---] followers, [---] engagements


"$ARGX Catalyst Date - 2025-04-05 Drug - VYVGART (efgartigimod alfa-fcab) Treatment - generalized myasthenia gravis (gMG) chronic inflammatory demyelinating polyneuropathy (CIDP) https://www.biopharmawatch.com/company/ARGX https://www.biopharmawatch.com/company/ARGX"  
[X Link](https://x.com/Biopharma_Watch/status/1907825477169086915)  2025-04-03T16:00Z [---] followers, [---] engagements


"Upcoming catalysts to watch in April [----] 📅: $RAPT $PMN $CLNN $GNTA $BOLD $THTX $REGN $BMY $NBTX $AMPG $BCAK $EOSI $EVAX $TLX $OCGN $SNTI $KURA $PMT $OBT For detailed insights 📷 https://biopharmawatch.com/fda-calendar https://biopharmawatch.com/fda-calendar"  
[X Link](https://x.com/Biopharma_Watch/status/1908846399388533049)  2025-04-06T11:37Z [----] followers, [---] engagements


"Top Market Movers: Positive News Full Access: $RENB 0.45$ 15.41% April [--] [----] Renovaro Provides Update to Definitive Agreement with Predictive Oncology https://biopharmawatch.com/market-movers https://biopharmawatch.com/market-movers"  
[X Link](https://x.com/Biopharma_Watch/status/1909274993017372753)  2025-04-07T16:00Z [----] followers, [---] engagements


"$RYTM 53.06$ 13.02% April [--] [----] Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase [--] TRANSCEND Trial Evaluating Setmelanotide in Patients with Acquired Hypothalamic Obesity"  
[X Link](https://x.com/Biopharma_Watch/status/1909274994783170792)  2025-04-07T16:00Z [---] followers, [--] engagements


"Highest Volume Ticker - Price - Volume $BJDX - 7.90$ - 45.5M $PFE - 22.46$ - 40.1M $STSS - 0.02$ - 39.2M $ME - 0.61$ - 29.7M $CUTR - 0.10$ - 29.5M https://biopharmawatch.com/market-movers https://biopharmawatch.com/market-movers"  
[X Link](https://x.com/Biopharma_Watch/status/1909274999141154902)  2025-04-07T16:00Z [---] followers, [---] engagements


"$XENE 30.95$ 5.27% April [--] [----] Xenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 2025"  
[X Link](https://x.com/Biopharma_Watch/status/1909275022960525561)  2025-04-07T16:00Z [---] followers, [--] engagements


"$ARGX Catalyst Date - 2025-04-10 Drug - VYVGART SC (efgartigimod alfa and hyaluronidase-qvfc) Treatment - Generalized Myasthenia Gravis (gMG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) https://www.biopharmawatch.com/company/ARGX https://www.biopharmawatch.com/company/ARGX"  
[X Link](https://x.com/Biopharma_Watch/status/1909275023866548663)  2025-04-07T16:00Z [---] followers, [--] engagements


"$ALMS 7.92$ -21.30% April [--] [----] Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger"  
[X Link](https://x.com/Biopharma_Watch/status/1909637400768262610)  2025-04-08T16:00Z [---] followers, [--] engagements


"$AWH 0.09$ -7.24% April [--] [----] Aspira Appoints Three New Directors Executes $2.0 Million Equity Purchase Agreement"  
[X Link](https://x.com/Biopharma_Watch/status/1909637415179805124)  2025-04-08T16:00Z [----] followers, [--] engagements


"$ARGX Catalyst Date - 2025-04-10 Drug - VYVGART SC (efgartigimod alfa and hyaluronidase-qvfc) Treatment - Generalized Myasthenia Gravis (gMG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) https://www.biopharmawatch.com/company/ARGX https://www.biopharmawatch.com/company/ARGX"  
[X Link](https://x.com/Biopharma_Watch/status/1909637416270676301)  2025-04-08T16:00Z [---] followers, [---] engagements


"Unusual Volume Ticker - Avg Vol - Cur Vol - Unusual Ratio $ECOR - 92.7K - 239.6K - [----] $STAA - 1.2M - 2.3M - [----] $TARA - 264.7K - 411.2K - [----] https://biopharmawatch.com/market-movers https://biopharmawatch.com/market-movers"  
[X Link](https://x.com/anyuser/status/1909999774742241568)  2025-04-09T16:00Z [----] followers, [---] engagements


"$ARGX Catalyst Date - 2025-04-10 Drug - VYVGART SC (efgartigimod alfa and hyaluronidase-qvfc) Treatment - Generalized Myasthenia Gravis (gMG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) https://www.biopharmawatch.com/company/ARGX https://www.biopharmawatch.com/company/ARGX"  
[X Link](https://x.com/Biopharma_Watch/status/1909999775279182213)  2025-04-09T16:00Z [---] followers, [---] engagements


"$REGN Catalyst Date - 2025-04-20 Drug - EYLEA HD (aflibercept [--] mg) Treatment - Wet Age-Related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) https://www.biopharmawatch.com/company/REGN https://www.biopharmawatch.com/company/REGN"  
[X Link](https://x.com/Biopharma_Watch/status/1909999812524515443)  2025-04-09T16:00Z [---] followers, [---] engagements


"Highest Volume Ticker - Price - Volume $STSS - 0.03$ - 1.4B $RSLS - 0.60$ - 139.8M $KTTA - 1.60$ - 92.6M $PRFX - 2.25$ - 70.8M $CDT - 0.83$ - 31.8M https://biopharmawatch.com/market-movers https://biopharmawatch.com/market-movers"  
[X Link](https://x.com/Biopharma_Watch/status/1910362162628874372)  2025-04-10T16:00Z [---] followers, [---] engagements


"Unusual Volume Ticker - Avg Vol - Cur Vol - Unusual Ratio $ECOR - 92.7K - 239.6K - [----] $STAA - 1.2M - 2.3M - [----] $TARA - 264.7K - 411.2K - [----] https://biopharmawatch.com/market-movers https://biopharmawatch.com/market-movers"  
[X Link](https://x.com/Biopharma_Watch/status/1910362163006316585)  2025-04-10T16:00Z [---] followers, [---] engagements


"$REGN Catalyst Date - 2025-04-20 Drug - EYLEA HD (aflibercept [--] mg) Treatment - Wet Age-Related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) https://www.biopharmawatch.com/company/REGN https://www.biopharmawatch.com/company/REGN"  
[X Link](https://x.com/Biopharma_Watch/status/1910362178038739033)  2025-04-10T16:00Z [---] followers, [--] engagements


"Top Market Movers: Positive News Full Access: $ONCY 0.59$ 18.06% April [--] [----] Oncolytics Biotech and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and P https://biopharmawatch.com/market-movers https://biopharmawatch.com/market-movers"  
[X Link](https://x.com/Biopharma_Watch/status/1910724545037684962)  2025-04-11T16:00Z [---] followers, [---] engagements


"$REGN Catalyst Date - 2025-04-20 Drug - EYLEA HD (aflibercept [--] mg) Treatment - Wet Age-Related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) https://www.biopharmawatch.com/company/REGN https://www.biopharmawatch.com/company/REGN"  
[X Link](https://x.com/Biopharma_Watch/status/1910724561542263139)  2025-04-11T16:00Z [---] followers, [--] engagements


"$ARGX 580.02$ 6.19% April [--] [----] argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy"  
[X Link](https://x.com/Biopharma_Watch/status/1910724574024450226)  2025-04-11T16:00Z [---] followers, [--] engagements


"Latest catalysts: $SXTP Catalyst Date - 2025-04-15 Drug - tafenoquine (ARAKODA) Treatment - babesiosis https://biopharmawatch.com/fda-calendar https://biopharmawatch.com/fda-calendar"  
[X Link](https://x.com/Biopharma_Watch/status/1911811718914728174)  2025-04-14T16:00Z [---] followers, [---] engagements


"Highest Volume Ticker - Price - Volume $STSS - 0.04$ - 826.5M $THTX - 2.77$ - 52.3M $PTN - 0.19$ - 44.0M $ME - 0.61$ - 29.7M $CUTR - 0.10$ - 29.5M https://biopharmawatch.com/market-movers https://biopharmawatch.com/market-movers"  
[X Link](https://x.com/Biopharma_Watch/status/1911811719527014865)  2025-04-14T16:00Z [---] followers, [---] engagements


"Unusual Volume Ticker - Avg Vol - Cur Vol - Unusual Ratio $ECOR - 92.7K - 239.6K - [----] $STAA - 1.2M - 2.3M - [----] $TARA - 264.7K - 411.2K - [----] https://biopharmawatch.com/market-movers https://biopharmawatch.com/market-movers"  
[X Link](https://x.com/Biopharma_Watch/status/1911811719665451103)  2025-04-14T16:00Z [---] followers, [---] engagements


"$REGN Catalyst Date - 2025-04-20 Drug - EYLEA HD (aflibercept [--] mg) Treatment - Wet Age-Related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) https://www.biopharmawatch.com/company/REGN https://www.biopharmawatch.com/company/REGN"  
[X Link](https://x.com/Biopharma_Watch/status/1911811733854863764)  2025-04-14T16:00Z [---] followers, [--] engagements


"$LLY 839.96$ 14.30% April [--] [----] Lilly's oral GLP-1 orforglipron demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase [--] trial"  
[X Link](https://x.com/Biopharma_Watch/status/1913344294557225083)  2025-04-18T21:30Z [---] followers, [--] engagements


"Latest catalysts: $REGN Catalyst Date - 2025-04-20 Drug - EYLEA HD (aflibercept [--] mg) Treatment - Wet Age-Related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) https://biopharmawatch.com/fda-calendar https://biopharmawatch.com/fda-calendar"  
[X Link](https://x.com/Biopharma_Watch/status/1913344297950417391)  2025-04-18T21:30Z [---] followers, [---] engagements


"Highest Volume Ticker - Price - Volume $STSS - 0.03$ - 391.7M $ADGM - 1.78$ - 115.5M $PFE - 22.14$ - 54.1M $SXTC - 2.16$ - 51.7M $CHRO - 1.84$ - 39.6M https://biopharmawatch.com/market-movers https://biopharmawatch.com/market-movers"  
[X Link](https://x.com/Biopharma_Watch/status/1913344298097193340)  2025-04-18T21:30Z [----] followers, [---] engagements


"Unusual Volume Ticker - Avg Vol - Cur Vol - Unusual Ratio $ECOR - 92.7K - 239.6K - [----] $STAA - 1.2M - 2.3M - [----] $TARA - 264.7K - 411.2K - [----] https://biopharmawatch.com/market-movers https://biopharmawatch.com/market-movers"  
[X Link](https://x.com/Biopharma_Watch/status/1913344298508321017)  2025-04-18T21:30Z [---] followers, [---] engagements


"$BMY Catalyst Date - 2025-04-21 Drug - Opdivo (nivolumab) plus Yervoy (ipilimumab) Treatment - Unresectable hepatocellular carcinoma (HCC) https://www.biopharmawatch.com/company/BMY https://www.biopharmawatch.com/company/BMY"  
[X Link](https://x.com/Biopharma_Watch/status/1913344298814501048)  2025-04-18T21:30Z [---] followers, [---] engagements


"Highest Volume Ticker - Price - Volume $STSS - 0.03$ - 158.9M $RSLS - 0.38$ - 150.7M $UPXI - 9.89$ - 99.9M $APVO - 0.64$ - 56.9M $PFE - 22.04$ - 31.8M https://biopharmawatch.com/market-movers https://biopharmawatch.com/market-movers"  
[X Link](https://x.com/Biopharma_Watch/status/1914431464785240231)  2025-04-21T21:30Z [---] followers, [---] engagements


"$EOLS 10.38$ -3.80% April [--] [----] Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April [--] 2025"  
[X Link](https://x.com/Biopharma_Watch/status/1914431498956259612)  2025-04-21T21:30Z [---] followers, [--] engagements


"Latest catalysts: $BCAX Catalyst Date - 2025-04-25 Drug - ficerafusp alfa Treatment - metastatic or advanced cutaneous squamous cell carcinoma (cSCC) https://biopharmawatch.com/fda-calendar https://biopharmawatch.com/fda-calendar"  
[X Link](https://x.com/Biopharma_Watch/status/1915069415605109122)  2025-04-23T15:45Z [---] followers, [---] engagements


"$TLX Catalyst Date - 2025-04-26 Drug - TLX101-CDx Treatment - Characterization of progressive or recurrent glioma from treatment-related changes in adult and pediatric patients. https://www.biopharmawatch.com/company/TLX https://www.biopharmawatch.com/company/TLX"  
[X Link](https://x.com/Biopharma_Watch/status/1915069458361770223)  2025-04-23T15:45Z [---] followers, [--] engagements


"Highest Volume Ticker - Price - Volume $OCEA - 0.02$ - 171.4M $STSS - 0.02$ - 73.8M $CERO - 1.04$ - 62.2M $BCTX - 7.23$ - 34.1M $ME - 0.61$ - 29.7M https://biopharmawatch.com/market-movers https://biopharmawatch.com/market-movers"  
[X Link](https://x.com/Biopharma_Watch/status/1915431805148409982)  2025-04-24T15:45Z [---] followers, [---] engagements


"Latest catalysts: $BCAX Catalyst Date - 2025-04-25 Drug - ficerafusp alfa Treatment - metastatic or advanced cutaneous squamous cell carcinoma (cSCC) https://biopharmawatch.com/fda-calendar https://biopharmawatch.com/fda-calendar"  
[X Link](https://x.com/Biopharma_Watch/status/1915431805324583216)  2025-04-24T15:45Z [---] followers, [---] engagements


"$TLX Catalyst Date - 2025-04-26 Drug - TLX101-CDx Treatment - Characterization of progressive or recurrent glioma from treatment-related changes in adult and pediatric patients. https://www.biopharmawatch.com/company/TLX https://www.biopharmawatch.com/company/TLX"  
[X Link](https://x.com/Biopharma_Watch/status/1915431842700026271)  2025-04-24T15:45Z [---] followers, [---] engagements


"$TLX 19.17$ 4.76% April [--] [----] Telix Reports US$186M Q1 Revenue Up 62% YOY"  
[X Link](https://x.com/Biopharma_Watch/status/1915431842993619159)  2025-04-24T15:45Z [---] followers, [---] engagements


"Top Market Movers: Positive News Full Access: $TNFA 0.21$ 11.98% April [--] [----] TNF Pharmaceuticals and Renova Health Utilize AI to Accelerate Drug Development https://biopharmawatch.com/market-movers https://biopharmawatch.com/market-movers"  
[X Link](https://x.com/anyuser/status/1915794186617626633)  2025-04-25T15:45Z [----] followers, [---] engagements


"Latest catalysts: $CGON Catalyst Date - 2025-04-26 Drug - Cretostimogene Grenadenorepvec Treatment - High-risk BCG-unresponsive non-muscle invasive bladder cancer https://biopharmawatch.com/fda-calendar https://biopharmawatch.com/fda-calendar"  
[X Link](https://x.com/Biopharma_Watch/status/1915794191000703271)  2025-04-25T15:45Z [---] followers, [---] engagements


"Highest Volume Ticker - Price - Volume $OCEA - 0.02$ - 171.4M $STSS - 0.02$ - 39.2M $AZTR - 0.31$ - 38.9M $ME - 0.61$ - 29.7M $CUTR - 0.10$ - 29.5M https://biopharmawatch.com/market-movers https://biopharmawatch.com/market-movers"  
[X Link](https://x.com/Biopharma_Watch/status/1915794191252328797)  2025-04-25T15:45Z [---] followers, [---] engagements


"$TARA Catalyst Date - 2025-04-26 Drug - TARA-002 Treatment - non-muscle invasive bladder cancer (NMIBC) https://www.biopharmawatch.com/company/TARA https://www.biopharmawatch.com/company/TARA"  
[X Link](https://x.com/Biopharma_Watch/status/1915794191839564197)  2025-04-25T15:45Z [---] followers, [--] engagements


"$TLX Catalyst Date - 2025-04-26 Drug - TLX101-CDx Treatment - Characterization of progressive or recurrent glioma from treatment-related changes in adult and pediatric patients. https://www.biopharmawatch.com/company/TLX https://www.biopharmawatch.com/company/TLX"  
[X Link](https://x.com/Biopharma_Watch/status/1915794207564062983)  2025-04-25T15:45Z [---] followers, [---] engagements


"Top Market Movers: Negative News Full Access: $TARA 3.51$ -18.75% April [--] [----] Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase [--] ADVANCED-2 Trial of TARA-002 in https://biopharmawatch.com/market-movers https://biopharmawatch.com/market-movers"  
[X Link](https://x.com/Biopharma_Watch/status/1916881354089963652)  2025-04-28T15:45Z [---] followers, [---] engagements


"Highest Volume Ticker - Price - Volume $OCEA - 0.02$ - 171.4M $SWTX - 46.19$ - 62.1M $GLMD - 1.86$ - 54.8M $BON - 0.06$ - 41.9M $ME - 0.61$ - 29.7M https://biopharmawatch.com/market-movers https://biopharmawatch.com/market-movers"  
[X Link](https://x.com/Biopharma_Watch/status/1916881356195508568)  2025-04-28T15:45Z [---] followers, [---] engagements


"$SWTX 46.19$ 3.28% April [--] [----] SpringWorks Therapeutics Announces Expected CHMP Opinion in Q2 [----] for Nirogacestat for the Treatment of Adults with Desmoid Tumors in the European Union"  
[X Link](https://x.com/Biopharma_Watch/status/1916881384133788095)  2025-04-28T15:45Z [---] followers, [---] engagements


"Top Market Movers: Negative News Full Access: $SNTI 3.18$ -12.64% April [--] [----] Senti Bios SENTI-202 a First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy Demonstrates Positive Pr https://biopharmawatch.com/market-movers https://biopharmawatch.com/market-movers"  
[X Link](https://x.com/Biopharma_Watch/status/1917243743444586608)  2025-04-29T15:45Z [---] followers, [---] engagements


"Latest catalysts: $INAB Catalyst Date - 2025-04-30 Drug - Gamma-delta T cell engager platform Treatment - Cancer immunotherapy https://biopharmawatch.com/fda-calendar https://biopharmawatch.com/fda-calendar"  
[X Link](https://x.com/Biopharma_Watch/status/1917243744631574549)  2025-04-29T15:45Z [---] followers, [---] engagements


"$BCTX 4.61$ -7.80% April [--] [----] BriaCell Therapeutics Announces Closing of $13.8 million Public Offering"  
[X Link](https://x.com/Biopharma_Watch/status/1917243744732233965)  2025-04-29T15:45Z [---] followers, [--] engagements


"Unusual Volume Ticker - Avg Vol - Cur Vol - Unusual Ratio $ECOR - 92.7K - 239.6K - [----] $HALO - 1.0M - 1.5M - [----] $MRNA - 13.6M - 18.9M - [----] https://biopharmawatch.com/market-movers https://biopharmawatch.com/market-movers"  
[X Link](https://x.com/Biopharma_Watch/status/1917243744874840434)  2025-04-29T15:45Z [---] followers, [--] engagements


"$REGN 568.51$ -6.93% April [--] [----] Lynozyfic (linvoseltamab) Approved in the European Union for the Treatment of Relapsed/Refractory Multiple Myeloma"  
[X Link](https://x.com/Biopharma_Watch/status/1917243754110652730)  2025-04-29T15:45Z [---] followers, [--] engagements


"$BOLT Catalyst Date - 2025-04-30 Drug - BDC-3042 Treatment - Non-small cell lung cancer triple-negative breast cancer clear cell renal cell carcinoma colorectal cancer melanoma ovarian cancer https://www.biopharmawatch.com/company/BOLT https://www.biopharmawatch.com/company/BOLT"  
[X Link](https://x.com/Biopharma_Watch/status/1917243781948313812)  2025-04-29T15:45Z [---] followers, [--] engagements


"Unusual Volume Ticker - Avg Vol - Cur Vol - Unusual Ratio $ECOR - 92.7K - 239.6K - [----] $HALO - 1.0M - 1.5M - [----] $MRNA - 13.6M - 18.9M - [----] https://biopharmawatch.com/market-movers https://biopharmawatch.com/market-movers"  
[X Link](https://x.com/Biopharma_Watch/status/1917606130643263943)  2025-04-30T15:45Z [---] followers, [---] engagements


"Latest catalysts: $PROF Catalyst Date - 2025-04 Drug - TULSA-PRO Treatment - Prostate cancer benign prostatic hyperplasia (BPH) https://biopharmawatch.com/fda-calendar https://biopharmawatch.com/fda-calendar"  
[X Link](https://x.com/Biopharma_Watch/status/1917606130844590238)  2025-04-30T15:45Z [----] followers, [---] engagements


"Highest Volume Ticker - Price - Volume $PTPI - 0.01$ - 446.9M $OCEA - 0.02$ - 171.4M $GCTK - 0.19$ - 41.9M $ME - 0.61$ - 29.7M $CUTR - 0.10$ - 29.5M https://biopharmawatch.com/market-movers https://biopharmawatch.com/market-movers"  
[X Link](https://x.com/Biopharma_Watch/status/1917606130878144632)  2025-04-30T15:45Z [---] followers, [---] engagements


"Top Market Movers: Positive News Full Access: $AMRN 11.39$ 5.85% April [--] [----] Amarin to Report First Quarter [----] Financial Results and Host Conference Call on May [--] [----] https://biopharmawatch.com/market-movers https://biopharmawatch.com/market-movers"  
[X Link](https://x.com/Biopharma_Watch/status/1917968515669409969)  2025-05-01T15:45Z [---] followers, [---] engagements


"Unusual Volume Ticker - Avg Vol - Cur Vol - Unusual Ratio $ECOR - 92.7K - 239.6K - [----] $HALO - 1.0M - 1.5M - [----] $MRNA - 13.6M - 18.9M - [----] https://biopharmawatch.com/market-movers https://biopharmawatch.com/market-movers"  
[X Link](https://x.com/Biopharma_Watch/status/1917968520874463711)  2025-05-01T15:45Z [---] followers, [---] engagements


"Highest Volume Ticker - Price - Volume $OCEA - 0.02$ - 171.4M $RNAZ - 0.58$ - 59.3M $ME - 0.61$ - 29.7M $CUTR - 0.10$ - 29.5M $WBA - 18.72$ - 28.8M https://biopharmawatch.com/market-movers https://biopharmawatch.com/market-movers"  
[X Link](https://x.com/Biopharma_Watch/status/1917968521113510106)  2025-05-01T15:45Z [---] followers, [---] engagements


"$PHAT 3.40$ -20.74% April [--] [----] Phathom Pharmaceuticals to Present VOQUEZNA (vonoprazan) Data at DDW [----] Annual Meeting"  
[X Link](https://x.com/Biopharma_Watch/status/1917968521168036339)  2025-05-01T15:45Z [---] followers, [--] engagements


"$TLX 17.88$ 2.76% April [--] [----] Telixs Illuccix PSMA-PET Imaging Agent Approved in France"  
[X Link](https://x.com/Biopharma_Watch/status/1917968547365765501)  2025-05-01T15:45Z [---] followers, [--] engagements


"Unusual Volume Ticker - Avg Vol - Cur Vol - Unusual Ratio $ECOR - 92.7K - 239.6K - [----] $HALO - 1.0M - 1.5M - [----] $MRNA - 13.6M - 18.9M - [----] https://biopharmawatch.com/market-movers https://biopharmawatch.com/market-movers"  
[X Link](https://x.com/Biopharma_Watch/status/1918330906559058008)  2025-05-02T15:45Z [---] followers, [---] engagements


"Highest Volume Ticker - Price - Volume $PLRZ - 0.70$ - 216.8M $OCEA - 0.02$ - 171.4M $RSLS - 0.41$ - 113.7M $ME - 0.61$ - 29.7M $CUTR - 0.10$ - 29.5M https://biopharmawatch.com/market-movers https://biopharmawatch.com/market-movers"  
[X Link](https://x.com/Biopharma_Watch/status/1918330907674722471)  2025-05-02T15:45Z [---] followers, [---] engagements


"Top Market Movers: Positive News Full Access: $IMMP 2.29$ 33.91% May [--] [----] Immuteps Efti in Combination with KEYTRUDA (pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer with CPS [--] https://biopharmawatch.com/market-movers https://biopharmawatch.com/market-movers"  
[X Link](https://x.com/Biopharma_Watch/status/1919418063784686008)  2025-05-05T15:45Z [----] followers, [---] engagements


"Latest catalysts: $AVIR Catalyst Date - 2025-05-07 Drug - Bemnifosbuvir and Ruzasvir Treatment - Hepatitis C virus (HCV) infection https://biopharmawatch.com/fda-calendar https://biopharmawatch.com/fda-calendar"  
[X Link](https://x.com/Biopharma_Watch/status/1919418069413478746)  2025-05-05T15:45Z [----] followers, [---] engagements


"$UBX Catalyst Date - 2025-05-07 Drug - UBX1325 (senolytic candidate) Treatment - Diabetic Macular Edema https://www.biopharmawatch.com/company/UBX https://www.biopharmawatch.com/company/UBX"  
[X Link](https://x.com/Biopharma_Watch/status/1919418085498659146)  2025-05-05T15:45Z [---] followers, [--] engagements


"$UBX 1.17$ 4.46% May [--] [----] UNITY Biotechnology Announces Complete 36-Week Results from the ASPIRE Phase 2b Study of UBX1325 in Diabetic Macular Edema and Provides Corporate Updates"  
[X Link](https://x.com/Biopharma_Watch/status/1919418101176860912)  2025-05-05T15:45Z [---] followers, [--] engagements


"$MDGL Catalyst Date - 2025-05-07 Drug - Resmetirom (formerly known as Rezdiffra) Treatment - Metabolic dysfunction-associated steatohepatitis (MASH) compensated MASH cirrhosis https://www.biopharmawatch.com/company/MDGL https://www.biopharmawatch.com/company/MDGL"  
[X Link](https://x.com/Biopharma_Watch/status/1919418117446643954)  2025-05-05T15:45Z [---] followers, [---] engagements


"Unusual Volume Ticker - Avg Vol - Cur Vol - Unusual Ratio $ECOR - 92.7K - 239.6K - [----] $HALO - 1.0M - 1.5M - [----] $MRNA - 13.6M - 18.9M - [----] https://biopharmawatch.com/market-movers https://biopharmawatch.com/market-movers"  
[X Link](https://x.com/Biopharma_Watch/status/1919780458289889506)  2025-05-06T15:45Z [---] followers, [---] engagements


"Latest catalysts: $AVIR Catalyst Date - 2025-05-07 Drug - Bemnifosbuvir and Ruzasvir Treatment - Hepatitis C virus (HCV) infection https://biopharmawatch.com/fda-calendar https://biopharmawatch.com/fda-calendar"  
[X Link](https://x.com/Biopharma_Watch/status/1919780458411520398)  2025-05-06T15:45Z [----] followers, [---] engagements


"Highest Volume Ticker - Price - Volume $KTTA - 1.92$ - 196.1M $OCEA - 0.02$ - 171.4M $ME - 0.61$ - 29.7M $CUTR - 0.10$ - 29.5M $WBA - 18.72$ - 28.8M https://biopharmawatch.com/market-movers https://biopharmawatch.com/market-movers"  
[X Link](https://x.com/Biopharma_Watch/status/1919780458512151017)  2025-05-06T15:45Z [---] followers, [---] engagements


"$CYCC 0.34$ 13.42% May [--] [----] CYCLACEL PHARMACEUTICALS INC. ANNOUNCES EXECUTION OF SHARE EXCHANGE AGREEMENT TO MAKE FITTERS SDN. BHD. ITS WHOLLY-OWNED SUBSIDIARY TO ACCELERATE GROWTH AND STOCKHOLDER VALUE"  
[X Link](https://x.com/Biopharma_Watch/status/1919780484957274392)  2025-05-06T15:45Z [---] followers, [--] engagements


"$UBX Catalyst Date - 2025-05-07 Drug - UBX1325 (senolytic candidate) Treatment - Diabetic Macular Edema https://www.biopharmawatch.com/company/UBX https://www.biopharmawatch.com/company/UBX"  
[X Link](https://x.com/Biopharma_Watch/status/1919780488740573202)  2025-05-06T15:45Z [---] followers, [--] engagements


"$NXL 1.27$ -4.56% May [--] [----] Nexalin Technology Announces Pricing of $5.0 Million Public Offering of Common Stock"  
[X Link](https://x.com/Biopharma_Watch/status/1919780496470671755)  2025-05-06T15:45Z [---] followers, [---] engagements


"Top Market Movers: Negative News Full Access: $PTN 0.10$ -42.18% May [--] [----] Palatin Technologies Announces Pricing of up to $23 Million Public Offering https://biopharmawatch.com/market-movers https://biopharmawatch.com/market-movers"  
[X Link](https://x.com/Biopharma_Watch/status/1920142845631213609)  2025-05-07T15:45Z [---] followers, [---] engagements


"Latest catalysts: $SNTI Catalyst Date - 2025-05-08 Drug - SENTI-202 Treatment - Relapsed/Refractory AML https://biopharmawatch.com/fda-calendar https://biopharmawatch.com/fda-calendar"  
[X Link](https://x.com/Biopharma_Watch/status/1920142847296299219)  2025-05-07T15:45Z [---] followers, [---] engagements


"Highest Volume Ticker - Price - Volume $OCEA - 0.02$ - 171.4M $ZVSA - 0.65$ - 61.0M $TOVX - 0.75$ - 44.3M $ME - 0.61$ - 29.7M $CUTR - 0.10$ - 29.5M https://biopharmawatch.com/market-movers https://biopharmawatch.com/market-movers"  
[X Link](https://x.com/Biopharma_Watch/status/1920142847451500846)  2025-05-07T15:45Z [---] followers, [---] engagements


"$TLX Catalyst Date - 2025-05-09 Drug - TLX101 (131I-iodofalan) Treatment - Recurrent high-grade glioma (brain cancer) https://www.biopharmawatch.com/company/TLX https://www.biopharmawatch.com/company/TLX"  
[X Link](https://x.com/Biopharma_Watch/status/1920142863062704297)  2025-05-07T15:45Z [---] followers, [--] engagements


"Upcoming Biotech Catalysts to Watch This Week: $CLSD $SNTI $PSTV $TLX 🔍 Full Calendar: http://biopharmawatch.com/fda-calendar http://biopharmawatch.com/fda-calendar"  
[X Link](https://x.com/anyuser/status/1920188980055978035)  2025-05-07T18:48Z [----] followers, [---] engagements


"Latest catalysts: $TLX Catalyst Date - 2025-05-09 Drug - TLX101 (131I-iodofalan) Treatment - Recurrent high-grade glioma (brain cancer) https://biopharmawatch.com/fda-calendar https://biopharmawatch.com/fda-calendar"  
[X Link](https://x.com/Biopharma_Watch/status/1920505235300372777)  2025-05-08T15:45Z [---] followers, [---] engagements


"Unusual Volume Ticker - Avg Vol - Cur Vol - Unusual Ratio $ECOR - 92.7K - 239.6K - [----] $STAA - 1.2M - 2.3M - [----] $TARA - 264.7K - 411.2K - [----] https://biopharmawatch.com/market-movers https://biopharmawatch.com/market-movers"  
[X Link](https://x.com/Biopharma_Watch/status/1920505236109865387)  2025-05-08T15:45Z [---] followers, [---] engagements


"$CPRX 22.14$ -5.61% May [--] [----] Catalyst Pharmaceuticals Reports Record First Quarter [----] Financial Results and Provides Business Update"  
[X Link](https://x.com/Biopharma_Watch/status/1920505256733257973)  2025-05-08T15:45Z [---] followers, [--] engagements


"$VTRS 9.35$ 8.66% May [--] [----] Viatris Announces Positive Top-Line Results from Two Pivotal Phase [--] Studies of Novel Fast-Acting Meloxicam (MR-107A-02) for the Treatment of Moderate-to-Severe Acute Pain"  
[X Link](https://x.com/Biopharma_Watch/status/1920505271010660544)  2025-05-08T15:45Z [---] followers, [--] engagements


"Top Market Movers: Negative News Full Access: $PLX 1.91$ -34.08% May [--] [----] Protalix BioTherapeutics Reports First Quarter [----] Financial and Business Results https://biopharmawatch.com/market-movers https://biopharmawatch.com/market-movers"  
[X Link](https://x.com/Biopharma_Watch/status/1920867622725579256)  2025-05-09T15:45Z [---] followers, [---] engagements


"Latest catalysts: $GANX Catalyst Date - 2025-05-10 Drug - GT-02287 (A Clinical-stage Allosteric GCase Modulator) Treatment - Parkinsons disease https://biopharmawatch.com/fda-calendar https://biopharmawatch.com/fda-calendar"  
[X Link](https://x.com/Biopharma_Watch/status/1920867624755528016)  2025-05-09T15:45Z [----] followers, [---] engagements


"$BOLT Catalyst Date - 2025-05-12 Drug - BDC-3042 Treatment - cancer https://www.biopharmawatch.com/company/BOLT https://www.biopharmawatch.com/company/BOLT"  
[X Link](https://x.com/Biopharma_Watch/status/1920867659757088836)  2025-05-09T15:45Z [---] followers, [--] engagements


"$SOLV 63.89$ -4.50% May [--] [----] Solventum Reports First Quarter [----] Financial Results"  
[X Link](https://x.com/Biopharma_Watch/status/1920867669156434181)  2025-05-09T15:45Z [---] followers, [---] engagements


"Upcoming PDUFA Catalysts to Watch This Month: $ARQT $LQDA $MRK $ETON $MRNA 🔍 Full Calendar: http://biopharmawatch.com/fda-calendar http://biopharmawatch.com/fda-calendar"  
[X Link](https://x.com/anyuser/status/1920920904554463435)  2025-05-09T19:16Z [----] followers, [----] engagements


"Top Market Movers: Negative News Full Access: $SHPH 0.21$ -11.46% May [--] [----] Shuttle Pharma FDA Orphan-Drug Nears Patient Enrollment Milestone for Phase [--] Clinical Trial https://biopharmawatch.com/market-movers https://biopharmawatch.com/market-movers"  
[X Link](https://x.com/Biopharma_Watch/status/1921954785689034785)  2025-05-12T15:45Z [---] followers, [---] engagements


"Highest Volume Ticker - Price - Volume $OCEA - 0.02$ - 171.4M $CTMX - 1.81$ - 88.4M $NCNA - 0.04$ - 42.2M $PFE - 22.91$ - 34.4M $ME - 0.61$ - 29.7M https://biopharmawatch.com/market-movers https://biopharmawatch.com/market-movers"  
[X Link](https://x.com/Biopharma_Watch/status/1921954787492589738)  2025-05-12T15:45Z [---] followers, [---] engagements


"$PLX 1.59$ -7.27% May [--] [----] Protalix BioTherapeutics Reports First Quarter [----] Financial and Business Results"  
[X Link](https://x.com/Biopharma_Watch/status/1921954796602638580)  2025-05-12T15:45Z [---] followers, [--] engagements


"Top Market Movers: Positive News Full Access: $NGNE 17.70$ 20.16% May [--] [----] Neurogene Reports First Quarter [----] Financial Results and Highlights Recent Updates https://biopharmawatch.com/market-movers https://biopharmawatch.com/market-movers"  
[X Link](https://x.com/Biopharma_Watch/status/1922317168873709862)  2025-05-13T15:45Z [---] followers, [---] engagements


"Top Market Movers: Negative News Full Access: $PLX 1.46$ -15.12% May [--] [----] Protalix BioTherapeutics Reports First Quarter [----] Financial and Business Results https://biopharmawatch.com/market-movers https://biopharmawatch.com/market-movers"  
[X Link](https://x.com/Biopharma_Watch/status/1922317172619280782)  2025-05-13T15:45Z [---] followers, [---] engagements


"Latest catalysts: $CELC Catalyst Date - 2025-05-14 Drug - gedatolisib Treatment - HR+/HER2- advanced breast cancer https://biopharmawatch.com/fda-calendar https://biopharmawatch.com/fda-calendar"  
[X Link](https://x.com/Biopharma_Watch/status/1922317174359916961)  2025-05-13T15:45Z [---] followers, [---] engagements


"Highest Volume Ticker - Price - Volume $OCEA - 0.02$ - 171.4M $CTMX - 2.13$ - 114.1M $PFE - 23.09$ - 77.5M $NCNA - 0.04$ - 76.2M $PLRZ - 0.35$ - 76.0M https://biopharmawatch.com/market-movers https://biopharmawatch.com/market-movers"  
[X Link](https://x.com/Biopharma_Watch/status/1922317174364110988)  2025-05-13T15:45Z [---] followers, [---] engagements


"Unusual Volume Ticker - Avg Vol - Cur Vol - Unusual Ratio $ECOR - 92.7K - 239.6K - [----] $HALO - 1.0M - 1.5M - [----] $MRNA - 13.6M - 18.9M - [----] https://biopharmawatch.com/market-movers https://biopharmawatch.com/market-movers"  
[X Link](https://x.com/Biopharma_Watch/status/1922317174385029269)  2025-05-13T15:45Z [---] followers, [---] engagements


"$OCS 17.60$ -5.27% May [--] [----] Oculis Publishes Invitation to the Annual General Meeting"  
[X Link](https://x.com/Biopharma_Watch/status/1922317198410056025)  2025-05-13T15:45Z [---] followers, [--] engagements


"$CLDX 20.18$ 10.09% May [--] [----] Celldex Reports First Quarter [----] Financial Results and Provides Corporate Update"  
[X Link](https://x.com/Biopharma_Watch/status/1922317202293989490)  2025-05-13T15:45Z [---] followers, [--] engagements


"$SOLV 63.89$ -4.50% May [--] [----] Solventum Reports First Quarter [----] Financial Results"  
[X Link](https://x.com/Biopharma_Watch/status/1922317207968882779)  2025-05-13T15:45Z [---] followers, [--] engagements


"$HOWL Catalyst Date - 2025-05-15 Drug - WTX-124 (Interleukin-2 INDUKINE molecule) Treatment - solid tumors https://www.biopharmawatch.com/company/HOWL https://www.biopharmawatch.com/company/HOWL"  
[X Link](https://x.com/Biopharma_Watch/status/1922317210997157921)  2025-05-13T15:45Z [---] followers, [--] engagements


"Upcoming Phase [--] Catalysts to Watch in June $MREO $RNTX $SRPT $ANNX $VIR These biotechs are heading into critical Phase [--] clinical trial readouts with major implications for patients and pipelines. 🔎 Full Catalyst Calendar: http://biopharmawatch.com/fda-calendar http://biopharmawatch.com/fda-calendar"  
[X Link](https://x.com/anyuser/status/1922397138132119994)  2025-05-13T21:02Z [----] followers, [----] engagements


"Top Market Movers: Positive News Full Access: $NGNE 17.70$ 20.16% May [--] [----] Neurogene Reports First Quarter [----] Financial Results and Highlights Recent Updates https://biopharmawatch.com/market-movers https://biopharmawatch.com/market-movers"  
[X Link](https://x.com/Biopharma_Watch/status/1922679555858583741)  2025-05-14T15:45Z [---] followers, [---] engagements


"Top Market Movers: Negative News Full Access: $PLX 1.46$ -15.12% May [--] [----] Protalix BioTherapeutics Reports First Quarter [----] Financial and Business Results https://biopharmawatch.com/market-movers https://biopharmawatch.com/market-movers"  
[X Link](https://x.com/Biopharma_Watch/status/1922679560191238172)  2025-05-14T15:45Z [---] followers, [---] engagements


"Unusual Volume Ticker - Avg Vol - Cur Vol - Unusual Ratio $ECOR - 92.7K - 239.6K - [----] $HALO - 1.0M - 1.5M - [----] $MRNA - 13.6M - 18.9M - [----] https://biopharmawatch.com/market-movers https://biopharmawatch.com/market-movers"  
[X Link](https://x.com/Biopharma_Watch/status/1922679561713770965)  2025-05-14T15:45Z [---] followers, [---] engagements


"$PCRX Catalyst Date - 2025-05-15 Drug - PCRX-201 (enekinragene inzadenovec) Treatment - osteoarthritis of the knee https://www.biopharmawatch.com/company/PCRX https://www.biopharmawatch.com/company/PCRX"  
[X Link](https://x.com/Biopharma_Watch/status/1922679577077518707)  2025-05-14T15:45Z [----] followers, [--] engagements


"$CLDX 20.18$ 10.09% May [--] [----] Celldex Reports First Quarter [----] Financial Results and Provides Corporate Update"  
[X Link](https://x.com/Biopharma_Watch/status/1922679587139682429)  2025-05-14T15:45Z [---] followers, [--] engagements


"$OCS 17.60$ -5.27% May [--] [----] Oculis Publishes Invitation to the Annual General Meeting"  
[X Link](https://x.com/Biopharma_Watch/status/1922679590654521839)  2025-05-14T15:45Z [---] followers, [--] engagements


"Top Market Movers: Positive News Full Access: $NGNE 17.70$ 20.16% May [--] [----] Neurogene Reports First Quarter [----] Financial Results and Highlights Recent Updates https://biopharmawatch.com/market-movers https://biopharmawatch.com/market-movers"  
[X Link](https://x.com/Biopharma_Watch/status/1923041944282046565)  2025-05-15T15:45Z [---] followers, [---] engagements


"Latest catalysts: $SLDB Catalyst Date - 2025-05-17 Drug - SGT-003 (next-generation gene therapy product candidate) Treatment - Duchenne muscular dystrophy https://biopharmawatch.com/fda-calendar https://biopharmawatch.com/fda-calendar"  
[X Link](https://x.com/Biopharma_Watch/status/1923041948706931183)  2025-05-15T15:45Z [----] followers, [---] engagements


"Top Market Movers: Negative News Full Access: $PLX 1.46$ -15.12% May [--] [----] Protalix BioTherapeutics Reports First Quarter [----] Financial and Business Results https://biopharmawatch.com/market-movers https://biopharmawatch.com/market-movers"  
[X Link](https://x.com/Biopharma_Watch/status/1923041948711125402)  2025-05-15T15:45Z [---] followers, [---] engagements


"$CLDX 20.18$ 10.09% May [--] [----] Celldex Reports First Quarter [----] Financial Results and Provides Corporate Update"  
[X Link](https://x.com/Biopharma_Watch/status/1923041970622263682)  2025-05-15T15:45Z [---] followers, [--] engagements


"$CNTB Catalyst Date - 2025-05-18 Drug - Rademikibart (anti-interleukin-4-receptor alpha antibody) Treatment - Moderate-to-severe asthma COPD https://www.biopharmawatch.com/company/CNTB https://www.biopharmawatch.com/company/CNTB"  
[X Link](https://x.com/Biopharma_Watch/status/1923041973537210455)  2025-05-15T15:45Z [----] followers, [--] engagements


"$OCS 17.60$ -5.27% May [--] [----] Oculis Publishes Invitation to the Annual General Meeting"  
[X Link](https://x.com/Biopharma_Watch/status/1923041981175038112)  2025-05-15T15:45Z [---] followers, [--] engagements


"$SOLV 63.89$ -4.50% May [--] [----] Solventum Reports First Quarter [----] Financial Results"  
[X Link](https://x.com/Biopharma_Watch/status/1923041996282921062)  2025-05-15T15:45Z [---] followers, [--] engagements


"Unusual Volume Ticker - Avg Vol - Cur Vol - Unusual Ratio $ECOR - 92.7K - 239.6K - [----] $HALO - 1.0M - 1.5M - [----] $MRNA - 13.6M - 18.9M - [----] https://biopharmawatch.com/market-movers https://biopharmawatch.com/market-movers"  
[X Link](https://x.com/Biopharma_Watch/status/1923404345070207320)  2025-05-16T15:45Z [---] followers, [---] engagements


"Latest catalysts: $SLDB Catalyst Date - 2025-05-17 Drug - SGT-003 (next-generation gene therapy product candidate) Treatment - Duchenne muscular dystrophy https://biopharmawatch.com/fda-calendar https://biopharmawatch.com/fda-calendar"  
[X Link](https://x.com/Biopharma_Watch/status/1923404345284137006)  2025-05-16T15:45Z [----] followers, [---] engagements


"$CNTB Catalyst Date - 2025-05-18 Drug - Rademikibart (anti-interleukin-4-receptor alpha antibody) Treatment - Moderate-to-severe asthma COPD https://www.biopharmawatch.com/company/CNTB https://www.biopharmawatch.com/company/CNTB"  
[X Link](https://x.com/Biopharma_Watch/status/1923404372429660252)  2025-05-16T15:45Z [----] followers, [--] engagements


"Top Market Movers: Negative News Full Access: $APLT 0.51$ -15.79% May [--] [----] Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late- https://biopharmawatch.com/market-movers https://biopharmawatch.com/market-movers"  
[X Link](https://x.com/Biopharma_Watch/status/1924491505865203827)  2025-05-19T15:45Z [---] followers, [---] engagements


"$BON 1.38$ -13.48% May [--] [----] BON Announces The Launch Of Its Postbiotic Hypoglycemic Patented Ingredient Product Series And Its Cooperation Agreement"  
[X Link](https://x.com/Biopharma_Watch/status/1924491510021816542)  2025-05-19T15:45Z [---] followers, [--] engagements


"🔬 Upcoming Pre-Clinical Readouts to Watch These early-stage biotech programs have key data updates on the horizon: 📅 $ALXO May [--] EGFR-expressing tumors (PoA: 65%) 📅 $GRI May [--] iNKT cell activator (PoA: 20%) 📅 $NLSP May [--] Dual orexin receptor (PoA: 10%) 📅 $TERN June [--] CML therapy (PoA: 85%) 🧠 At BiopharmaWatch we maintain a live curated calendar of critical biotech milestones including trial readouts regulatory decisions and FDA meetings updated daily for clarity and speed. 🔗 See the full catalyst tracker here: #Biopharma #DrugDevelopment #FDAcalendar #ClinicalTrials #LifeSciences"  
[X Link](https://x.com/anyuser/status/1924540937235267728)  2025-05-19T19:01Z [----] followers, [---] engagements


"Unusual Volume Ticker - Avg Vol - Cur Vol - Unusual Ratio $ECOR - 92.7K - 239.6K - [----] $STAA - 1.2M - 2.3M - [----] $TARA - 264.7K - 411.2K - [----] https://biopharmawatch.com/market-movers https://biopharmawatch.com/market-movers"  
[X Link](https://x.com/Biopharma_Watch/status/1925216280883138987)  2025-05-21T15:45Z [---] followers, [---] engagements


"$WAT 352.69$ -2.60% May [--] [----] Waters Acquires Halo Labs Expanding Biological Analysis Portfolio"  
[X Link](https://x.com/Biopharma_Watch/status/1925216290530021789)  2025-05-21T15:45Z [---] followers, [--] engagements


"$TVRD 29.30$ 5.62% May [--] [----] Tvardi Therapeutics to Participate in Upcoming Investor Conferences"  
[X Link](https://x.com/Biopharma_Watch/status/1925216314051690541)  2025-05-21T15:45Z [----] followers, [---] engagements


"Latest catalysts: $LQDA Catalyst Date - 2025-05-24 Drug - YUTREPIA (treprostinil) inhalation powder Treatment - Pulmonary Arterial Hypertension (PAH) Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) https://biopharmawatch.com/fda-calendar https://biopharmawatch.com/fda-calendar"  
[X Link](https://x.com/anyuser/status/1925941052579385410)  2025-05-23T15:45Z [----] followers, [----] engagements


"Unusual Volume Ticker - Avg Vol - Cur Vol - Unusual Ratio $ECOR - 92.7K - 239.6K - [----] $STAA - 1.2M - 2.3M - [----] $TARA - 264.7K - 411.2K - [----] https://biopharmawatch.com/market-movers https://biopharmawatch.com/market-movers"  
[X Link](https://x.com/Biopharma_Watch/status/1925941053481259126)  2025-05-23T15:45Z [---] followers, [---] engagements


"$MRK Catalyst Date - 2025-05-26 Drug - WELIREG (belzutifan) Treatment - Advanced unresectable or metastatic pheochromocytoma and paraganglioma (PPGL) https://www.biopharmawatch.com/company/MRK https://www.biopharmawatch.com/company/MRK"  
[X Link](https://x.com/Biopharma_Watch/status/1925941071021789363)  2025-05-23T15:45Z [---] followers, [---] engagements


"🎯 ASCO Season = Catalyst Season The biotech world is gearing up for the American Society of Clinical Oncology (ASCO) Annual Meeting and several companies are lining up big data drops ahead of the event 👇 📅 May [--] 🔹 $AFMD Acimtamig (innate cell engager) 📊 PoA: 60% Strong ORR/CR in R/R cHL RMAT status 🔹 $INAB INB-200 (gamma-delta T-cell therapy) 📊 PoA: 12% Early GBM data promising PFS still Phase [--] 📅 May [--] 🔹 $CYTK Aficamten (cardiac myosin inhibitor) 📊 PoA: 75% Positive Phase [--] for HCM BTD granted 🔹 $IOVA Amtagvi (lifileucel) 📊 PoA: 85% TIL therapy with 5-yr OS accelerated approval"  
[X Link](https://x.com/Biopharma_Watch/status/1926033759826039014)  2025-05-23T21:53Z [---] followers, [---] engagements


"Unusual Volume Ticker - Avg Vol - Cur Vol - Unusual Ratio $ECOR - 92.7K - 239.6K - [----] $STAA - 1.2M - 2.3M - [----] $TARA - 264.7K - 411.2K - [----] https://biopharmawatch.com/market-movers https://biopharmawatch.com/market-movers"  
[X Link](https://x.com/Biopharma_Watch/status/1927028217472237989)  2025-05-26T15:45Z [---] followers, [---] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing